[go: up one dir, main page]

WO2018066956A1 - Composition comprenant un extrait composite contenant du schisandrae fructus pour prévenir ou traiter une maladie liée à la circulation sanguine - Google Patents

Composition comprenant un extrait composite contenant du schisandrae fructus pour prévenir ou traiter une maladie liée à la circulation sanguine Download PDF

Info

Publication number
WO2018066956A1
WO2018066956A1 PCT/KR2017/011049 KR2017011049W WO2018066956A1 WO 2018066956 A1 WO2018066956 A1 WO 2018066956A1 KR 2017011049 W KR2017011049 W KR 2017011049W WO 2018066956 A1 WO2018066956 A1 WO 2018066956A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
schisandra chinensis
composition
blood circulation
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/011049
Other languages
English (en)
Korean (ko)
Inventor
김호경
김동선
성윤영
박선행
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Publication of WO2018066956A1 publication Critical patent/WO2018066956A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts

Definitions

  • the present invention is a composition for the prevention or treatment of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient, a method for treating a blood circulation-related disorder comprising administering the composition to an individual in need thereof, Schisandra chinensis It relates to a quasi-drug composition, feed additives and health functional food composition for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing.
  • Hyperlipidemia is a disease caused by increased blood lipids such as cholesterol in blood circulation and blood lipids attached to the artery wall. Chronic inflammatory reactions and narrowing of the arterial wall cause blood vessels to harden. Atherosclerosis is induced, and in the long run, clots generated therefrom block coronary arteries and cerebrovascular vessels, causing myocardial infarction, stroke and cerebral infarction.
  • drugs for treating hyperlipidemia are used as statin drugs that have inhibitory activity against HMG-CoA reductase, which plays an important role in the synthesis of cholesterol in the liver. It is known to have side effects such as muscle toxicity.
  • hypertension is a condition in which the arterial blood pressure is chronically high, and systolic blood pressure is 140 mmHg or more or diastolic blood pressure is 90 mmHg or more in an adult 18 years or older, and arteriosclerosis is a fat containing cholesterol, phospholipids, and calcium. Plaque accumulates in the vascular lining, causing the arteries to become rigid, losing elasticity, and narrowing. Eventually, the arterial rupture, detachment, etc. occur due to impaired blood supply or increased pressure.
  • drugs for inhibiting hypertension drugs for inhibiting angiotensin converting enzyme activity or drugs for inhibiting binding between angiotensin and angiotensin receptors
  • various statins which are HMG-CoA reductase inhibitors, are used for the treatment of atherosclerosis.
  • statins which are HMG-CoA reductase inhibitors
  • the therapeutic agent is also known to have side effects when used for a long time, there is still a need for the development of a more effective therapeutic agent.
  • the present inventors have made efforts to develop natural substances that have no side effects and are effective in blood circulation-related diseases including hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke or cerebral infarction, etc.
  • the present invention was completed by confirming that Schizandra chinensis-C extract or Schizandra chinensis complex extract inhibited thrombus formation and inhibited platelet aggregation, which is effective in preventing, improving or treating blood circulation-related diseases.
  • An object of the present invention to provide a pharmaceutical composition for the prevention or treatment of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
  • Another object of the present invention is to provide a method for treating a blood circulation related disease, comprising administering the pharmaceutical composition for preventing or treating the blood circulation related disease to an individual in need thereof.
  • Another object of the present invention to provide a quasi-drug composition for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
  • Another object of the present invention to provide a feed additive for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
  • Another object of the present invention to provide a health functional food composition for the prevention or improvement of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
  • the complex extract containing Schisandra chinensis of the present invention in particular, Schisandra chinensis extract or Schisandra chinensis complex extract can be effectively used for the prevention or treatment of blood circulation-related diseases by inhibiting thrombus formation and effectively inhibiting platelet aggregation.
  • the composition can be used as a quasi-drug composition, health functional food composition, or feed additives for the prevention or improvement of blood circulation-related diseases.
  • 1 is a graph showing the thrombus formation inhibitory ability of Schizandra chinensis extract of various ratios.
  • Figure 2 is a graph showing the thrombus generation inhibitory ability of Schizandra chinensis compound extract of various ratios.
  • Figure 3 is a graph showing the antithrombotic activity of Schizandra chinensis, Turmeric alone and Schizandra chimus extract.
  • Figure 4 is a graph showing the thrombus formation inhibitory ability of Schizandra chinensis, S. chinensis extract and Schizandra chinensis combined extract.
  • Figure 5 is a graph showing the platelet aggregation inhibitory ability of Schizandra chinensis complex extract of various ratios.
  • Figure 6 is a graph showing the platelet aggregation inhibitory ability of Schizandra chinensis compound extract of various ratios.
  • Figure 7 is a graph comparing the thrombus generation inhibitory ability of the known Schizandra-containing 19 species complex extract and Schizandra complex extract of the present invention.
  • Figure 8 is a graph comparing the platelet aggregation inhibitory ability of the known Schizandra-containing 19 species complex extract and Schizandra complex extract of the present invention.
  • One aspect of the present invention for achieving the above object is for the prevention or treatment of blood circulation-related diseases comprising a complex extract containing Schisandra chinensis, specifically, Schisandra chinensis complex extract or Schisandra chinensis complex extract as an active ingredient. It provides a pharmaceutical composition.
  • the present invention provides a preventive or therapeutic use of blood circulation-related diseases of the composition comprising a complex extract containing Schisandra chinensis, specifically Schisandra chinensis complex extract or Schisandra chinensis extract as an active ingredient.
  • Schisandra chinesis in the present invention means a ball-shaped dark red fruit having a diameter of about 1 cm, and contains 1 to 2 red juices and reddish brown seeds. Types include North Schisandra chinensis, South Schisandra chinensis and Black Schisandra chinensis, and it contains ingredients such as cezandrarin, gomisin, citric acid, malic acid and citric acid.It is known to be used as a tonic by strengthening the heart, lowering blood pressure and enhancing immunity. have. Schisandra may be purchased and used commercially, or may be collected or grown in nature, but is not limited thereto.
  • curcumae Longae Rhizoma in the present invention, also called ulumum (Tumeric), means a perennial herb of Ginger-necked ginger family, which has been used as a herbal medicine in oriental medicine.
  • Turmeric has a spicy and bitter taste, the outside of the rhizome is light yellow, and the inside is scarlet and has a camphor-like scent. It is also known that flowering ear comes out before the leaves, and yellow flowers bloom in the leaf axes in April and June.
  • Turmeric may also be purchased and used commercially, or may be one that is collected or cultivated in nature, but is not limited thereto.
  • the stem, leaf, or root portion of turmeric may be used, but is not limited thereto.
  • mulberry leaf in the present invention refers to the leaves of the mulberry (Morus alba L.), which is a deciduous broad-leaved arboreous tree belonging to the rose family Mulberry family, and in Oriental medicine, it refers to a medicinal herb obtained by drying the leaves of the mulberry tree.
  • Mulberry leaves can be harvested annually and contain high amounts of secondary metabolites such as flavonoids and alkaloids.
  • the upper leaf may also be purchased and used commercially, or may be used collected or cultivated in nature, but is not limited thereto, and the portion used may use the leaf of the mulberry leaf as the meaning of the upper leaf.
  • extract is an extract containing Schisandra chinensis, and may include an extract extracted Schisandra chinensis alone.
  • composite extract in the present invention means an extract containing two or more substances, specifically, an extract containing one or more substances other than Schisandra chinensis, more specifically, Schisandra chinensis extract Or Schizandra chinensis compound extract, but is not limited thereto.
  • the complex extract is a mixture of Schisandra chinensis and other substances other than Schisandra chinensis extract, and Schicho and Schisandra chinensis extract, respectively, to prepare an extract and then to extract the extract, specifically, turmeric or lettuce in Schisandra chinensis It may include, but is not limited to, an extract obtained by mixing turmeric or upper leaf extract with the extracted extract and Schisandra chinensis extract.
  • the extract is a low alcohol of 1 (C1) to 4 (C4) carbon, such as water, methanol, ethanol, etc. in a volume of about 1 to 20 times the dry weight, specifically about 3 to 5 times the dry weight of each component Elution with a polar solvent such as or a mixed solvent having a mixing ratio of about 1: 0.1 to 1:10, but is not limited thereto,
  • the extraction temperature is 20 °C to 100 °C, specifically 60 °C to 100 °C Can be extracted, but is not limited thereto.
  • the extraction period may be an extract extracted using an extraction method such as hot water extraction, cold needle extraction, reflux cooling extraction or ultrasonic extraction for about 1 hour to 4 days, but may exhibit a therapeutic effect of the blood circulation-related diseases of the present invention.
  • the extract is not limited thereto, and may include all extracts, dilutions or concentrates of the extracts, dried products obtained by drying the extracts, or all of these modifiers or purified products.
  • the Schisandra chinensis extract, turmeric extract, upper leaf extract can be extracted from various organs of natural, hybrid, mutant plants, for example, roots, ground, stems, leaves, flowers, trunks of fruits, bark of fruit as well as plant tissue culture Extractable from water.
  • the Schisandra chinensis extract and turmeric extract may include Schisandra chinensis extract and turmeric extract in a weight ratio of 0.1 to 10: 1, specifically, but may include 0.5 to 2: 1 by weight, but is not limited thereto.
  • the Schisandra chinensis and upper leaf complex extract may include Schisandra chinensis extract and the upper leaf extract in a weight ratio of 0.1 to 10: 1, specifically, may comprise a weight ratio of 0.25 to 1: 1, but is not limited thereto.
  • the composition may inhibit thrombus formation, and in particular, may have a platelet aggregation inhibitory ability, and thus may be used for the prevention or treatment of a number of blood circulation-related diseases including thrombosis.
  • blood circulation related disease refers to various diseases caused by metabolic problems or caused by blood clots, and the complex extract containing Schisandra chinensis of the present invention can be treated or prevented with an active ingredient.
  • Diseases that are present include, but are not limited to, one or more diseases selected from the group consisting of hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke and cerebral infarction.
  • hypolipidemia refers to a disease caused by a large amount of fat in the blood due to poor metabolism such as triglycerides and cholesterol, specifically, triglycerides in the blood, LDL cholesterol, phospholipids and free fatty acids, etc.
  • the lipid component of the increased state may include high cholesterol or hypertriglyceridemia, but is not limited thereto.
  • the term "hypertension” refers to a state in which the arterial blood pressure is chronically high, and the systolic blood pressure is 140 mmHg or more or the diastolic blood pressure is 90 mmHg or more in an adult 18 years or older, and may be caused by obesity or the like.
  • the term "arteriosclerosis” is a disease caused by the accumulation of fatty substances (plaque) containing cholesterol, phospholipids, calcium, etc. in the vascular lining, which causes the arteries to become hard, lose elasticity, and narrow, and thus inhibit blood supply or pressure. This means that the artery is ruptured or peeled off.
  • plaque fatty substances
  • myocardial infarction refers to a disease in which the heart muscle is suddenly blocked due to blood clots, spasms, or the like, and the heart muscle is damaged. It refers to a condition that refers to a condition in which no cause can be found other than a disease of cerebrovascular vessels. Specifically, a disease caused by blockage of the cerebrovascular vessels is called a cerebral infarction or ischemic stroke, and blood flows into the brain tissue due to the rupture of the cerebrovascular vessel. This outflow disease is called cerebral hemorrhage or hemorrhagic stroke.
  • the platelet obtained from the blood of the rat is reacted at different ratios of the Schizandra chinensis complex extract or Schizandra chinensis complex extract, and then platelet aggregation is promoted by adding collagen as a platelet aggregation promoter.
  • the mixture ratio of Schisandra chinensis was 0.25 to 4: 1
  • the Schisandra chinensis mixture ratio of 0.25 to 4: 1 has excellent platelet aggregation inhibitory ability.
  • the complex extract containing Schisandra chinensis of the present invention specifically, Schisandra chinensis complex extract or Schisandra chinensis complex extract can be used for the prevention or treatment of diseases related to blood circulation, in particular diseases caused by blood clots.
  • prevention refers to any action that inhibits or delays the development of blood circulation-related diseases such as hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke, and cerebral infarction by administration of a composition according to the present invention.
  • treatment refers to any action by which administration of a composition according to the present invention improves or advantageously alters the symptoms of the diseases.
  • the content of the complex extract containing Schisandra chinensis contained in the pharmaceutical composition according to an embodiment of the present invention is not particularly limited thereto, but is 0.0001 to 50% by weight based on the total weight of the final composition, more specifically 0.01 to It may be included in an amount of 5% by weight.
  • compositions of the invention as specific embodiments of the invention are pharmaceutical compositions.
  • the composition of the present invention is a pharmaceutical composition
  • the composition may include a pharmaceutically acceptable carrier.
  • composition comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
  • Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose (at least one compound). lactose) and gelatin.
  • lubricants such as magnesium stearate, talc and the like are also used.
  • Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, and syrups, and various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • the non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used.
  • the pharmaceutical composition is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories. It can have one formulation.
  • composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level is defined as the type and severity, age, sex, Activity, sensitivity to drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical arts.
  • a typical daily dosage of a composition comprising a complex extract containing Schisandra chinensis according to the invention as an active ingredient may range from 10 to 1,000 mg / kg, preferably 10 to 500 mg / kg, once or It can be administered in several divided doses.
  • the prophylactic or therapeutic agent for blood circulation-related diseases such as hyperlipidemia, hypertension, arteriosclerosis, myocardial infarction, stroke and cerebral infarction may be administered daily or intermittently, and the number of administrations per day is divided once or twice or three times. It is possible to administer.
  • the frequency of administration in the case where the two active ingredients are single drugs may be the same or different times.
  • Another aspect of the invention provides a method of treating a blood circulation related disease, comprising administering a complex extract containing Schisandra chinensis to a subject in need thereof.
  • the term "individual” refers to all animals including humans who have already developed or may have a blood circulation related disease, and by administering to the subject a composition comprising a complex extract containing Schisandra chinensis as an active ingredient, the disease Can be effectively prevented and treated.
  • the subject means an entire mammal including a dog, cow, horse, rabbit, mouse, rat, chicken or human, but the mammal of the present invention is not limited to the above examples.
  • the optimal amount and dosage interval of the individual doses of the composition of the present invention will be determined by the nature and extent of the disease being treated, the dosage form, the route and site, and the age and health of the particular patient being treated and ultimately used by the physician. It will be appreciated by those skilled in the art that the appropriate dosage will be determined. Such dosing can be repeated as often as appropriate. If side effects occur, the dosage and frequency can be altered or reduced in accordance with normal clinical practice.
  • the route of administration of the composition may be administered via any general route as long as it can reach the desired tissue.
  • the composition of the present invention may be administered as desired, but is not limited to intraperitoneal administration, intravenous administration, subcutaneous administration, intradermal administration, oral administration.
  • the composition may also be administered by any device in which the active agent may migrate to the target cell.
  • Another aspect of the present invention provides a quasi-drug composition comprising the complex composition as an active ingredient.
  • composition of the present invention may be added to the quasi-drug composition for the purpose of preventing or improving blood circulation related diseases.
  • the term " improvement" refers to an effect of alleviating the symptoms of blood circulation-related diseases such as hyperlipidemia or arteriosclerosis by applying a quasi-drug composition comprising a complex extract containing Schizandra chinensis of the present invention.
  • the term "quasi drug” refers to a fiber, rubber product or the like used for the purpose of treating, alleviating, treating or preventing a disease of a human or animal, has a weak action on the human body or does not directly act on the human body, Or non-machinery and the like, or any of the agents used for sterilization, insecticide and similar purposes for the purpose of preventing infection, for the purpose of diagnosing, treating, reducing, treating or preventing human or animal diseases.
  • Means the goods used are not instruments, machines or devices, and the items used for the purpose of pharmacologically affecting the structure and function of humans or animals except those which are not devices, machines or devices.
  • the quasi-drug may include external skin preparations or personal hygiene products.
  • the complex extract containing Schisandra chinensis of the present invention is used as an quasi-drug additive
  • the extract may be added as it is or used with other quasi-drugs or quasi-drug components, and may be appropriately used according to a conventional method, and the mixed amount of the active ingredient may be used. It may be appropriately determined depending on the purpose.
  • the external preparation for skin is not particularly limited thereto, but may be preferably used in the form of an ointment, lotion, spray, patch, cream, powder, suspension, gel or gel.
  • the personal hygiene products are not particularly limited, but preferably soap, cosmetics, wet wipes, tissue paper, shampoo, skin cream, face cream, toothpaste, lipstick, perfume, make-up, foundation, ball touch, mascara, eye shadow, Sunscreen lotions, hair care products, air freshener gels or cleaning gels.
  • another example of the quasi-drug composition of the present invention is a disinfectant cleaner, shower foam, gagreen, wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment or filter filler.
  • Another aspect of the present invention provides a feed additive for preventing or improving blood circulation-related diseases, including a complex extract containing Schisandra chinensis as an active ingredient.
  • the complex extract containing Schisandra chinensis of the present invention may be added to a feed additive or a feed composition comprising the feed additive for the purpose of preventing or improving blood circulation related diseases.
  • the term "feed additive” is a substance added to the feed for the purpose of various effects, such as supplementation of nutrients and weight loss prevention, improving the digestive availability of the fiber in the feed, improving the quality, prevention of reproduction disorders and improving conception, prevention of high temperature stress in summer Means.
  • the feed additive of the present invention corresponds to a feed supplement under the Feed Control Act, and includes mineral preparations such as sodium bicarbonate, bentonite, magnesium oxide, and composite minerals, mineral preparations such as trace minerals such as zinc, copper, cobalt, and selenium, and keratin.
  • Vitamins such as vitamin E, vitamin A, D, E, nicotinic acid, vitamin B complex, protective amino acids such as methionine, lyric acid, protective fatty acids such as fatty acid calcium salt, probiotics (lactic acid bacteria), yeast culture, mold Probiotics such as fermented products, yeasts and the like may be further included.
  • the term "feed” means any natural or artificial diet, one meal, or the like or any ingredient of the one meal for the animal to eat, ingest, and digest.
  • the feed comprising the composition for the prevention or treatment of blood circulation-related diseases according to the present invention as an active ingredient can be prepared in various forms of feed known in the art, specifically thick feed, forage and / or special Feed may be included.
  • the rich feed includes seed fruits containing grains such as wheat, oats and corn, and by-products obtained by refining grains, bran, beans, fluids, sesame seeds, linseed, coco, etc., including rice bran, bran and barley bran.
  • Fish soluble which is a concentrate of fresh liquids obtained from fish residues, fish residues, and fish residues such as by-products such as seaweed, sweet potatoes, and potatoes, which are the remaining components of starch residue. soluble), meat meal, blood meal, milk powder, skim milk powder, milk from cheese, and whey, the balance of manufacturing casein from skim milk, dried foods such as dried whey, yeast, chlorella, and seaweed. This is not restrictive.
  • raw vegetables such as grasses, grasses, and green grass, fodder turnips, fodder beets, and root vegetables such as Lutherbearger, a type of turnip, raw grass, green grass crops, and grains Silage (silage), grasses, grasses, and dried hay, straws of breeders, and leaves of legumes, which are filled and fermented by lactic acid fermentation, are not limited thereto.
  • Special feeds are supplemented with mineral feeds such as oyster shells and rock salts, urea feeds such as urea and its derivatives, diureide isobutane, and natural feed ingredients.
  • Feed additives and dietary supplements which are substances added in small amounts, are not limited thereto.
  • Feed composition comprising the composition for the prevention or treatment of blood circulation-related diseases according to the present invention can be prepared by adding a complex extract containing Schisandra chinensis in a suitable effective concentration range according to various feed production methods known in the art.
  • Feed composition according to the present invention is not particularly limited as long as it is an object for the purpose of preventing or treating blood circulation-related diseases, any one can be applied.
  • any one can be applied.
  • monkeys, dogs, cats, rabbits, morphotes, rats, mice, cows, sheep, pigs, goats and the like but not limited to, such as, but not limited to, and can be applied to any individual.
  • Another embodiment of the present invention provides a health functional food composition for preventing or improving blood circulation related diseases comprising a complex extract containing Schisandra chinensis as an active ingredient.
  • the complex extract containing Schisandra chinensis may be added to the dietary supplement composition for the purpose of preventing or improving blood circulation related diseases such as obesity, hyperlipidemia, hypertension, arteriosclerosis, hyperinsulinemia, diabetes, liver disease, and the like. .
  • the dietary supplement composition may include a food acceptable carrier.
  • Food compositions of the present invention include all forms of functional foods, nutritional supplements, health foods and food additives, and the like. It may be prepared in various forms according to known conventional methods.
  • the complex extract containing Schisandra chinensis can be added as it is or used together with other food or food ingredients, and can be suitably used according to a conventional method.
  • the mixed amount of the active ingredient can be determined suitably according to the purpose of use (prevention, health or therapeutic treatment).
  • the composite extract containing Schisandra chinensis in the preparation of food or beverage is added in an amount of 0.0001 to 1% by weight, preferably 0.001 to 0.1% by weight in the raw material composition.
  • the amount may be used below the above range.
  • Examples of foods to which the above substances can be added include dairy products including meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums and ice cream, various soups, beverages, teas and drinks. , Alcoholic beverages and vitamin complexes, and the like, may include all of the health food in the conventional sense.
  • the health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage.
  • the above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol.
  • sweetening agent natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used.
  • the ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 compositions of the present invention can be used.
  • the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage.
  • the proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
  • the composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. Although the proportion of such pulp is not critical, it is generally selected from the range of 0.01 to 10 parts by weight per 100 parts by weight of the composition of the present invention, these components can be used independently or in combination.
  • Mungyeong acid Schisandra chinensis (1 kg) and dried turmeric (1 kg) were respectively refluxed at 80 ° C. for 3 hours using 15 L of 70% ethanol (EtOH), and the filtrate was concentrated under reduced pressure at 50 ° C.
  • the concentrate was lyophilized to prepare Schizandra chinensis extract (340 g) and Turmeric extract (63 g).
  • each of the prepared Schisandra chinensis extract and turmeric extract were mixed in a weight ratio to prepare a complex extract having a ratio of Schisandra chinensis and 4: 1, 2: 1, 1: 1, 1: 2 and 1: 4, respectively.
  • Mungyeong acid Schisandra chinensis (1 kg) and dried upper leaves (1 kg) were respectively refluxed at 80 ° C. for 3 hours using 15 L of 70% ethanol (EtOH), and the filtrate was concentrated under reduced pressure at 50 ° C.
  • EtOH 70% ethanol
  • Each of the concentrates was lyophilized to prepare Schizandra chinensis extract (340 g) and upper leaf extract (179 g).
  • each of the Schisandra chinensis extract and the upper leaf extract was mixed in a weight ratio to prepare a complex extract having a ratio of Schisandra chinensis and the upper leaf 4: 1, 2: 1, 1: 1, 1: 2 and 1: 4, respectively.
  • Example 2 Evaluation of the Thrombotic Inhibitory Effect of Schisandra chinensis Extracts in Carageenan-induced Thrombus Animal Model
  • Example 1-1 200 mg / kg of Schisandra chinensis extract prepared in Example 1-1 was orally administered every 3 days before carrageenan injection with different ratios of Schisandra chinensis and turmeric, and orally administered 1 hour before carrageenan injection on the day of thrombus induction. Thereafter, oral administration was performed at 23 hours, 47 hours, or 71 hours after carrageenan injection.
  • tail thrombus formation length after 72 hours after carrageenan injection was measured and shown in FIG. 1.
  • the tail thrombus formation length observed at 72 hours after the injection of only carrageenan into rats was 2.85 cm on average, but when the complex extract containing Schisandra chinensis was injected, the inhibition rate was 4: 1. 52%, 47% for 2: 1, 77% for 1: 1, and 63% for 1: 2, the tail blood clot length was much shorter.
  • the composite extract of 1 person averaged about 1.10cm (p ⁇ 0.01) it was confirmed that it has the best thrombus inhibitory effect.
  • the complex extract containing Schisandra chinensis has a very good antithrombotic activity, and in particular, the ratio of Schisandra chinensis extract has the most excellent antithrombotic activity. .
  • the average tail thrombus generation length was 2.73 cm, but when injected with a complex extract containing Schisandra chinensis inhibition rate is 4: 1 39% of cases, 37% of cases of 2: 1, 69% of cases of 1: 1, 72% of cases of 1: 2, 53% of cases of 1: 4, and the length of tail blood clots was much shorter.
  • the average value of tail thrombus generation length was about 1.06 cm (p ⁇ 0.001), indicating that it had the best thrombus inhibitory ability.
  • the complex extract containing Schisandra chinensis has a very good antithrombotic activity, and in particular, the Schisandra chinensis extract has a very good antithrombotic activity.
  • Colby's E value calculated using 36% and 21% of inhibition rate is 49
  • the actual inhibition rate of the Schisandra chinensis extract is 84%, so the Schisandra chinensis extract of the present invention is much larger than the effect of the extract alone. It can be seen that there is a synergistic effect.
  • the value of Colby's Formula E calculated using 36% and 41% of inhibition rate is 62, respectively.
  • the actual inhibition rate of the Schisandra chinensis extract is 92%, and the Schisandra chinensis extract of the present invention is much larger than the effect of the extract alone. It can be seen that there is a synergistic effect.
  • Example 2-2 In order to confirm the ex-vivo platelet aggregation inhibitory effect of the extract of Schisandra chinensis, anesthesia was measured in Example 2-2, and anesthetized the SD rat, and then blood was slowly collected from the arterial blood in the abdominal cavity to obtain 3.2% sodium sheet. After immersing the blood in the tube containing the rate anticoagulant, the collected blood was centrifuged at 1,000 rpm for 10 minutes. Isolated platelet rich plasma (PRP) was diluted with platelet poor plasma obtained by centrifugation at 3,000 rpm for 10 minutes, and then used as a platelet count of 4.0 ⁇ 10 8 .
  • PRP Isolated platelet rich plasma
  • the platelet aggregation inhibitory activity is an optical method for confirming platelet aggregation through PRP, and the change of the electrical resistance and the light source according to the aggregation of platelets was measured.
  • 245 ⁇ l of blood was put in a cuvette and reacted for 10 minutes at 37 ° C. using a platelet agglomerate 700-2 (Chrono-Log.Havertown, PA).
  • 2.5 ⁇ l of extract samples were added to each sample for reaction.
  • 10 ⁇ g / ml of collagen which is a platelet aggregation promoter, was added and measured at 37 ° C. for up to 10 minutes while stirring at 1,200 rpm.
  • Example 2-3 In order to confirm the ex-vivo platelet aggregation inhibitory effect of the extract of Schisandra chinensis Fructus, anesthesia was measured in Example 2-3. Blood was placed in a tube containing anticoagulant. The collected blood was centrifuged at 1,000 rpm for 10 minutes. Isolated platelet rich plasma (PRP) was diluted with platelet poor plasma obtained by centrifugation at 3,000 rpm for 10 minutes, and then used as a platelet count of 4.0 ⁇ 10 8 .
  • PRP Isolated platelet rich plasma
  • the platelet aggregation inhibitory activity is an optical method for confirming platelet aggregation through PRP, and the change of the electrical resistance and the light source according to the aggregation of platelets was measured.
  • 245 ⁇ l of blood was put in a cuvette and reacted at 37 ° C. for 10 minutes using a platelet aggregator 700-2 (Chrono-Log.Havertown, PA).
  • 2.5 ⁇ l of extract samples were added to each sample for reaction.
  • 10 ⁇ g / ml of collagen which is a platelet aggregation promoter, was added and measured at 37 ° C. for up to 10 minutes while stirring at 1,200 rpm.
  • the well-known complex is Schisandra chinensis, buckwheat, barley, raw yellow sulfur, aquatic herb, rat eye bean, pork potato, red bean, red dog, turmeric, mulberry leaf, dermis, gujeolcho, chaga, ogapi, sewage, jujube, octopus, acorn It is a complex extract known to inhibit blood cholesterol and have blood vessel purification functions.
  • the known complex has almost no difference from the thrombus generation length when only carrageenan is injected, and thus, it has been found that there is almost no inhibition of thrombus generation.
  • Schisandra chinensis (1: 1) complex extract and Schisandra chinensis (1: 2) complex extract of the present invention as shown in Example 2, the average value of tail thrombus generation length was 1.10 cm and 1.06 cm, respectively.
  • the antithrombotic activity was significantly higher than that of only carrageenan injection, and it was confirmed that the antithrombotic activity was significantly superior to that of the known complex.
  • the Schizandra chinensis-containing extract of the present invention and the well-known complex were tested in the same manner as in Example 3 to compare the effect of inhibiting platelet aggregation.
  • the known complex was tested in two concentrations of 200 mg / kg and 400 mg / kg, using aspirin (25 mg / kg) as a positive control and collagen (10 ⁇ g / ml) as a platelet aggregation stimulating substance. It was. The result is as shown in FIG.
  • the known complexes have a statistical significance of 88.8% and 86.8% at the 200 mg / kg low dose when the S. aureus-S. Turmeric and S. aureus complexes are 100% when platelets are aggregated with collagen.
  • the known complex (prior art) showed 105.8% at the 200 mg / kg dose, which did not have a platelet aggregation inhibitory effect, and a high inhibitory effect of 92.5% at a high dose of 400 mg / kg. It can be seen that it does not have a known complex, although it contains all 17 other active ingredients in addition to turmeric and lettuce in Schizandra chinensis, the effect was significantly lower than the extract of the present invention.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Animal Husbandry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition comprenant un extrait composite contenant du Schisandrae Fructus en tant que principe actif pour prévenir ou traiter une maladie liée à la circulation sanguine, un procédé de traitement d'une maladie liée à la circulation sanguine, le procédé comprenant une étape d'administration de la composition à un sujet qui en a besoin et une composition quasi-médicamenteuse, un additif alimentaire et une composition alimentaire fonctionnelle de santé comprenant un extrait composite contenant du Schisandrae Fructus pour prévenir ou atténuer une maladie liée à la circulation sanguine. L'extrait composite contenant du Schisandrae Fructus de la présente invention, en particulier un extrait composite de Schisandrae Fructus-Curcumae Longae Rhizoma ou un extrait composite de Schisandrae Fructus-Mori Folium, inhibe la thrombogenèse et supprime efficacement l'agrégation plaquettaire et peut ainsi être utilisé efficacement dans la prévention ou le traitement d'une maladie liée à la circulation sanguine. De plus, la composition peut être appliquée et utilisée en tant que composition quasi-médicamenteuse, composition alimentaire fonctionnelle de santé ou additif alimentaire pour prévenir ou soulager une maladie liée à la circulation sanguine.
PCT/KR2017/011049 2016-10-04 2017-09-29 Composition comprenant un extrait composite contenant du schisandrae fructus pour prévenir ou traiter une maladie liée à la circulation sanguine Ceased WO2018066956A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160127754A KR101988579B1 (ko) 2016-10-04 2016-10-04 오미자를 함유하는 복합 추출물을 포함하는 혈액순환 관련 질환의 예방 또는 치료용 조성물
KR10-2016-0127754 2016-10-04

Publications (1)

Publication Number Publication Date
WO2018066956A1 true WO2018066956A1 (fr) 2018-04-12

Family

ID=61831088

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/011049 Ceased WO2018066956A1 (fr) 2016-10-04 2017-09-29 Composition comprenant un extrait composite contenant du schisandrae fructus pour prévenir ou traiter une maladie liée à la circulation sanguine

Country Status (2)

Country Link
KR (1) KR101988579B1 (fr)
WO (1) WO2018066956A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102471548B1 (ko) * 2020-07-02 2022-11-30 한두레축산 영농조합법인 오미자 사료 조성물, 이의 제조방법 및 오미자 사료 조성물을 이용한 한우 사육방법
KR102365311B1 (ko) * 2021-11-12 2022-02-23 이하양 생약 추출물을 포함하는 노령견용 사료 조성물 및 이의 제조방법
KR102853749B1 (ko) * 2025-01-24 2025-09-01 이대훈 반려동물용 심장 기능 개선용 조성물 및 이를 포함하는 영양제의 제조방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040057278A (ko) * 2002-12-26 2004-07-02 한국식품개발연구원 오미자 추출물을 이용한 심혈관 질환의 예방 및 치료용조성물
KR20060007105A (ko) * 2004-07-19 2006-01-24 이동웅 한약재와 곤약을 이용한 비만 또는 고지혈증의 치료 및예방용 약제학적 조성물
KR20070111623A (ko) * 2006-05-18 2007-11-22 동아대학교 산학협력단 한약재 추출물을 유효성분으로 함유하는 관상동맥성 심장 질환 또는 동맥경화증의 예방 또는 치료용 약학 조성물
KR101387685B1 (ko) * 2012-09-24 2014-04-21 이철우 오미자 추출물을 유효성분으로 함유하는 혈전증 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
KR20160013410A (ko) * 2014-07-25 2016-02-04 동의대학교 산학협력단 오미자 종자 추출물을 포함하는 혈관성 질환 예방 또는 개선용 조성물 및 그 제조 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329516B (en) * 2000-12-12 2010-09-01 Kaneka Corp Composition for preventing or ameliorating multiple risk factor syndromes and visceral fat-type obesity
KR20150026695A (ko) * 2013-08-30 2015-03-11 한국 한의학 연구원 상엽 알코올추출물을 유효성분으로 포함하는 혈전성 질환의 예방 및 치료용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040057278A (ko) * 2002-12-26 2004-07-02 한국식품개발연구원 오미자 추출물을 이용한 심혈관 질환의 예방 및 치료용조성물
KR20060007105A (ko) * 2004-07-19 2006-01-24 이동웅 한약재와 곤약을 이용한 비만 또는 고지혈증의 치료 및예방용 약제학적 조성물
KR20070111623A (ko) * 2006-05-18 2007-11-22 동아대학교 산학협력단 한약재 추출물을 유효성분으로 함유하는 관상동맥성 심장 질환 또는 동맥경화증의 예방 또는 치료용 약학 조성물
KR101387685B1 (ko) * 2012-09-24 2014-04-21 이철우 오미자 추출물을 유효성분으로 함유하는 혈전증 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
KR20160013410A (ko) * 2014-07-25 2016-02-04 동의대학교 산학협력단 오미자 종자 추출물을 포함하는 혈관성 질환 예방 또는 개선용 조성물 및 그 제조 방법

Also Published As

Publication number Publication date
KR20180037642A (ko) 2018-04-13
KR101988579B1 (ko) 2019-06-14

Similar Documents

Publication Publication Date Title
RU2350120C1 (ru) Добавка к пище и пищевой продукт, содержащий окрашенный в пурпурный цвет картофель, для больных, страдающих от ожирения (варианты)
WO2015030293A1 (fr) Composition contenant un extrait composite de raisin et de schisandra chinensis pour la prévention ou le traitement de maladies associées au syndrome métabolique
WO2018066956A1 (fr) Composition comprenant un extrait composite contenant du schisandrae fructus pour prévenir ou traiter une maladie liée à la circulation sanguine
KR20210052377A (ko) 캠퍼롤 및 에티카테킨 갈레이드를 포함하는 홍경천 추출물을 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물
KR101277266B1 (ko) 밀순 추출물을 유효성분으로 함유하는 비만증의 치료 및 예방을 위한 조성물
JP7385325B2 (ja) ロコモティブシンドローム改善用組成物
KR101018404B1 (ko) 정금나무 잎 추출물을 유효성분으로 함유하는 콜레스테롤 저하용 조성물
KR102737988B1 (ko) 벼룩나물 추출물을 유효성분으로 함유하는 관절염의 예방, 개선 또는 치료용 조성물
KR102275268B1 (ko) 갱년기 증상 또는 골다공증 개선용 조성물
KR20150050780A (ko) 까마귀쪽나무 추출물 또는 이의 분획물을 함유하는 비만 관련 질환의 예방 또는 치료용 조성물
KR20200022930A (ko) 우엉 추출물의 눈의 건강 증진 또는 눈 손상 예방을 위한 용도
KR102157413B1 (ko) 톱니모자반 추출물을 유효성분으로 포함하는 간 보호, 간질환 예방 또는 치료용 조성물
KR101516764B1 (ko) 환삼덩굴 추출물을 포함하는 간질환 또는 동맥경화의 예방 또는 치료용 조성물
KR102122408B1 (ko) 자감초 추출물을 유효성분으로 포함하는 남성갱년기 증후군의 예방, 개선 또는 치료용 조성물
KR101166852B1 (ko) 비타민나무잎 분말 또는 이의 추출물을 포함하는 체내 지질 개선 조성물
WO2018008999A1 (fr) Composition comprenant un extrait d'aster koraiensis ou une fraction de ce dernier en tant que principe actif servant à la régulation de la glycémie et à la prévention ou au traitement du diabète
KR102725586B1 (ko) 목서 추출물을 유효성분으로 함유하는 근육 질환의 예방, 개선 또는 치료용, 또는 운동수행능력 향상용 조성물
KR20140083493A (ko) 참모자반 추출물 또는 괭생이모자반 추출물을 유효성분으로 함유하는 항비만용 조성물
KR102347819B1 (ko) 갱년기 증상 또는 골다공증 개선용 조성물
KR100760386B1 (ko) Ａｃｐ 혼합생약 추출물을 포함하는 관절염의 예방 및 치료용 조성물
KR100686362B1 (ko) 청대추 추출물을 포함하는 비만의 치료 및 예방용 조성물
KR102233672B1 (ko) 엉겅퀴 및 돼지감자를 포함하는 혼합물을 함유하는 당뇨의 예방, 치료 또는 개선용 조성물
KR20230124337A (ko) 시트러스 계열 과일 추출물을 유효성분으로 포함하는 체중조절용 조성물
WO2023224305A1 (fr) Composition destinée à prévenir, atténuer ou traiter l'arthrite et la douleur articulaire, comprenant comme principe actif un extrait de lysimachia mauritiana
KR100776347B1 (ko) 신경세포 보호 활성이 있는 둥근마 추출물을 포함하는 뇌질환 예방 및 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17858750

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17858750

Country of ref document: EP

Kind code of ref document: A1